Total Funding
40
Total FundingPrivate Equity raised
Growth Score
pts
Heat Score
-4 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
87853
Kronos Bio focuses on the research and development of first-in-class therapies that modulate historically recalcitrant cancer.
Acquired by 
Concentra Biosciences
- Angela Koehler: Scientific Founder
- Christopher Wilfong: Chief Operating Officer and Co-FounderPast Role: Trustbridge Partners, Director
About the Company
Kronos Bio focuses on the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets.
It develops therapies that modulate historically undruggable targets. The company leverages deep capabilities in high-throughput small-molecule microarrays (SMM), targeted protein degradation, and cancer biology in
order to identify potent and selective compounds against transcription factors and other central drivers of oncogenic signaling.
Women Founded
